Introduction
Human milk is being explored intensively to understand its composition and physiological role for the breastfed infant. Lipids [
1,
2] have been identified as the most significant source of energy in mature milk. Additional important compounds of human milk are proteins, including enzymes and bioactive proteins like antibodies, nitrogenous compounds, and especially nucleotides, which influence the enzyme activity and the functionality of the immune system, hormones, vitamins, water and carbohydrates, including lactose and oligosaccharides. Together with lipids, lactose is an important source of energy, especially for the developing human brain [
3]. Human milk oligosaccharides (HMO) form the third largest solid fraction in human milk; they represent about 20% of the total carbohydrates, with an estimated amount of up to 20 g/L in colostrum [
4,
5]. HMO are composed of 5 different monosaccharides (Glc, Glucose; GlcNAc, N-Acetylglucosamine; Gal, Galactose; Fuc, Fucose; Neu5Ac, N-Acetylneuraminic acid), which are linked together via glycosidic bonds [
6] to produce a wide variety of different structures [
7].
HMO have been investigated for their potential role in the early growth of neonates; however, their effects in early and later metabolic health are unclear [
8‐
15]. To date, only 1 study has investigated the association between HMO and growth beyond infancy [
12]. The possible underlying biochemical or physiological processes linking HMO and infant growth are not understood. HMO are indigestible but can be fermented at least partly by the infant’s microbiome [
16‐
18]. Thus, they support the maturation of the gastrointestinal tract and the immune system and can protect against the colonization of pathogenic microorganisms by inhibiting their anchoring to human epithelial cells [
19‐
22]. In preclinical models, various studies have examined the effects of HMO (sometimes combined with microbiota) on gut epithelial maturation, differentiation and signaling processes [
23‐
25], which can affect nutrient uptake and developmental programming, as exemplified by their effects on bone formation [
26]. HMO concentrations are influenced by lactation stage and maternal genetic factors [
27‐
30] and probably to a lesser extent by maternal weight and body mass index (BMI) before pregnancy [
19,
27,
28].
Therefore, in this study, we aim to assess the association between the oligosaccharide composition in breast milk at 3 months postpartum and a) maternal factors (maternal age, pre-pregnancy BMI), b) the child’s birth parameters (anthropometric measurements, gestational age (GA)) and c) the subsequent growth until the age of 7 years (height, growth velocity, head circumference (HC), BMI). According to the literature, we hypothesize only weak associations between HMO concentrations and the maternal factors. Further, we expect associations between HMO and the child’s anthropometric measurements, with higher effects in the first year of life and lower effects for older ages.
Discussion
Our study aimed to investigate how HMO are associated with infant anthropometry from 3 months to 7 years of age and to identify any consistent patterns that could signify an important role of HMO for early growth. We found a consistent inverse association of growth velocity with LNnT only in NSC group. In addition, NSC had consistently higher BMI than SC. We also explored the influence of maternal and infant factors in HMO composition with maternal age, gestational age and pre-pregnancy BMI significantly associated with some of the HMO.
Recent studies proposed that HMO, besides their antimicrobial effects, may be involved in infant growth and development. HMO are indigestible but can be fermented, at least partially, by the infant’s microbiome [
16‐
18,
20,
40‐
42]. This promotes the growth and activity of commensal bacteria such as
Bifidobacterium and
Bacteroides spp. and supports the gastrointestinal tract’s maturation and the immune system [
43]. HMO may also reduce the risk of infections by protecting against colonization with pathogenic microorganisms. It is proposed that they can act as decoys, inhibiting the pathogen anchoring to the human epithelial cells [
21,
22,
44,
45].
It was recently suggested that sialylated oligosaccharides may exert a microbiota-dependent promotion of anabolic function in animal models by increasing the nutrient’s efficiency, promoting better growth and physical development [
46,
47]. Given the HMO-microbiome interaction and the microbiome’s proposed effect on nutrient efficiency, combined with maternal factors as pre-pregnancy BMI, the HMO composition of breast milk may also affect infant growth. Previous studies [
9,
10,
12‐
14] investigating associations between HMO and infant growth obtained conflicting results. Alderete et al. identified associations between LNFP-I and lower infantile weight, but not with pre-pregnancy BMI [
10]. In contrast, more recent studies found 2’FL positively associated with both child growth and pre-pregnancy BMI [
12,
13]. Other studies reported no associations between HMO composition or secretor status with child growth [
9,
14].
Despite the variability in results, 2 recent studies indicated a role of sialylated HMO in infant growth considering maternal BMI [
14,
48]. Binia et al. found moderate associations between HMO and infant growth and body composition during the first 4 months of life in a cohort of predominantly healthy babies and mothers with normal BMI. They reported significant associations of higher growth rate during the 4 months of lactation with higher 3′SL, expressed as Area Under the Curve of HMO concentrations at all visits, a potentially better measure of HMO exposure. Saben et al. confirmed the positive association of several sialylated HMO, including 3′SL but also total acidic HMO with infant growth during the first 6 months of life, including also mothers with obesity. The growth and body composition of the healthy infants were independent of maternal pre-pregnancy BMI. Interestingly, Saben et al. used calculated milk and HMO intake and not only concentrations, an attempt again to better quantify exposure to HMO. The study was limited to 1 single time-point of HMO quantification at 2 months. Both studies lacked the longer follow-up of infant growth, which could be a better indicator of future risk to obesity. Finally, neither of these 2 studies confirmed the previous observations by Lagström et al. [
12] and Larsson et al. [
13] on the positive association of 2’FL and the negative association of LNnT with infant growth. Another rare example of HMO intake being quantitatively measured looked at HMO intake at several time points up to 12 months. However, the total (not individual) HMO intake was calculated. They found higher HMO concentrations associated with higher percentages of the fat-free mass at 2, 5, 9, and 12 months of age, whereas fat mass was negatively related to higher HMO intake at 5, 9, and 12 months of age [
49].
Despite measuring HMO only at 3 months postpartum from only 20 mL of milk and no full breast expression, limiting insights on associations between growth and the changing HMO exposure over time, we could include growth data from birth until 7 years of age in a relatively strong sample size for this long follow-up compared to other studies. Indeed, we found higher BMI and HC SDS in NSC than SC. Although significance was not achieved at all time points, the probability of only positive results is
p < 0.002. Growth velocity but not BMI was inversely correlated with LNnT at 3 M–1Y and 1Y–2Y in NSC, supporting the findings from Lagström et al. [
12]. Regarding the association between infant growth and sialylated HMO 3′SL and 6′SL, we found a negative association with BMI-SDS in NSC but not with growth velocity, as previously reported [
14,
48]. Our study is an exploratory approach to identify associations between maternal, infant parameters and HMO. Our findings could be affected by false positive results, however the associations of growth velocity with LNnT and BMI with 2’FL are consistent for multiple time-points. We did not have milk intake measurements available in our study; future studies need to include these parameters to estimate more accurately the exposure of the infant gastrointestinal tract to HMO.
Included mothers had a mean BMI of 23.2 (3.78) kg/m
2 and a mean age of 30 years, similar to other study populations [
14,
48]. In line with previous results, we found a negative association between pre-pregnancy BMI and LNnT in NSM [
12]. However, other studies reported a positive or no association [
27,
28,
48]. This highlights the variability of reported HMO associations, reflecting possible differences in methods or non-measured confounders. Therefore, future studies examining the role of HMO in growth and metabolic health should consider maternal physiology and other human milk components, such as proteins and lipids.
One in vivo intervention study with sialylated oligosaccharides [
47] did report growth recovery following treatment with sialylated oligosaccharides in animal models of undernutrition. Recent randomized placebo controlled clinical trials testing infant formula containing specific individual HMO (2’FL or 2’FL and LNnT) effect on growth showed no differences in infant growth up to 12 months of age [
50,
51]. Their results may imply that the impact of single or a few HMO may not have a large effect in the growth of healthy infants. In addition, these trials were randomized, whereas observational studies are not and factors other than HMO may confound associations. Ideally, future intervention studies with HMO mixes closer to those in human milk should be followed beyond the first year of life. Observational studies like the present could highlight the importance of maternal and infant characteristics in the relationship between HMO and infant growth and development. The conflicting reported results however from recent observational data call for hypothesis-driven studies with detailed meta-data collection to test the specific role of groups rather than single HMO in influencing early growth and composition.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.